The therapy for invasive candidiasis related to biofilms infection remains a difficult medical problem. To overcome this problem, efforts have been made to search for novel antibiofilm agents from various sources. This study investigated the in vitro antibiofilm activity of (1)-N-2-methoxybenzyl-1,10-phenanthrolinium bromide (FEN) against Candida albicans. The minimum biofilm inhibitory concentration (MBIC) and minimum biofilm reduction concentration (MBRC) were determined using the MTT (3-(4-5-dimethylthiazol-2-yl)2,5-dyphenyl tetrazolium bromide) reduction assay. Biofilms on surfaces were visualized using scanning electron microscopy (SEM). This new compound inhibited the growth of C. albicans biofilms by 80 % with an MBIC₈₀ range from 0.5–2.0μg/mL. The ability of FEN to reduce 50 % of a preformed biofilm was demonstrated by defining a MBRC₅₀ range from 6.25–-12.5μg/mL. To reduce 80 % of a preformed biofilm required higher concentrations >200μg/mL. In addition, SEM images showed disruption of C. albicans biofilms matrix exposed to FEN. These results indicated that (1)-N-2-methoxybenzyl-1,10-phenanthrolinium bromide has the potential to be developed as a new antibiofilm agent against C. albicans.